Company news
Kiora Pharmaceuticals, Inc. news in 2023
Kiora Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
November 8, 2023
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
October 2, 2023
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
September 20, 2023
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
September 17, 2023
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
August 31, 2023
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
August 22, 2023
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
August 7, 2023
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
July 31, 2023
Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
July 4, 2023
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
June 14, 2023
Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
June 5, 2023
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
June 1, 2023
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
May 8, 2023
Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
April 20, 2023
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
April 16, 2023
Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
March 29, 2023
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
March 22, 2023
Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
March 9, 2023
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
February 6, 2023
Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
January 2, 2023
Decks in 2023
- Investor Presentation (November 2023)
Investor deck · 38 slides · Nov 9, 2023
- IPO Roadshow (May 2023)
IPO roadshow · 47 slides · May 15, 2023
- Investor Presentation (January 2023)
Investor deck · 28 slides · Jan 9, 2023